La catena delle opzioni mostra i dati chiave delle opzioni azionarie di American Oncology Network a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per American Oncology Network..

American Oncology Network (OTC:AONC) Azioni, Catena delle Opzioni

American Oncology Network

American Oncology Network Inc is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. The company pioneers healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. It is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care needed to achieve optimal health outcomes.

AMER ONCOLOGY NETWORK A by American Oncology Network, Inc.

American Oncology Network Inc

American Oncology Network Inc Warrants (31/03/2028)

2024 Outlook
The company raised its 2024 outlook for organic revenue growth to reflect strong year-to-date performance. All other measures in the outlook were maintained.
The company's outlook for 2024 in the table below assumes constant currency rates and excludes the impact of any future acquisitions or dispositions that may occur during the remainder of the year. Thomson Reuters believes that this type of guidance provides useful insight into the anticipated performance of its businesses.
The company expects its fourth-quarter 2024 organic revenue growth to be approximately 5% and its adjusted EBITDA margin to be approximately 37%.
The company continues to operate in an uncertain macroeconomic environment, reflecting ongoing geopolitical risk, uneven economic growth and an evolving interest rate and inflationary backdrop. Any worsening of the global economic or business environment, among other factors, could impact the company's ability to achieve its outlook.
Reported Full-Year 2023 Results and Full-Year 2024 Outlook
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Total Thomson Reuters</td>
<td colspan="1" rowspan="1">
FY 2023
Reported
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
2/8/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
5/2/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
8/1/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
11/5/2024
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenue Growth</td>
<td colspan="1" rowspan="1">3&nbsp;%</td>
<td colspan="1" rowspan="1">~ 6.5%</td>
<td colspan="1" rowspan="1">6.5% - 7.0%</td>
<td colspan="1" rowspan="1">~ 7.0%</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Organic Revenue Growth(1)</td>
<td colspan="1" rowspan="1">6&nbsp;%</td>
<td colspan="1" rowspan="1">~ 6%</td>
<td colspan="1" rowspan="1">6.0% - 6.5%</td>
<td colspan="1" rowspan="1">~ 6.5%</td>
<td colspan="1" rowspan="1">~7.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA Margin(1)</td>
<td colspan="1" rowspan="1">39.3&nbsp;%</td>
<td colspan="1" rowspan="1">~ 38%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Corporate Costs</td>
<td colspan="1" rowspan="1">$115 million</td>
<td colspan="1" rowspan="1">$120 - $130 million</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow(1)</td>
<td colspan="1" rowspan="1">$1.9 billion</td>
<td colspan="1" rowspan="1">~ $1.8 billion</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Accrued Capex as % of Revenues(1)</td>
<td colspan="1" rowspan="1">7.8&nbsp;%</td>
<td colspan="1" rowspan="1">~ 8.5%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Depreciation &amp; Amortization of Computer Software
&nbsp;&nbsp;&nbsp; Depreciation &amp; Amortization of Internally
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Developed Software
&nbsp;&nbsp;&nbsp; Amortization of Acquired Software
</td>
<td colspan="1" rowspan="1">
$628 million
 $556 million
$72 million
</td>
<td colspan="1" rowspan="1">
$730 - $750 million
 $595 - $615 million
~ $135 million
</td>
<td colspan="1" rowspan="1">
Unchanged
 Unchanged
Unchanged
</td>
<td colspan="1" rowspan="1">
Unchanged
 $580 - $600 million
~ $150 million
</td>
<td colspan="1" rowspan="1">
Unchanged
 Unchanged
Unchanged
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest Expense (P&amp;L)(2)</td>
<td colspan="1" rowspan="1">$164 million(2)</td>
<td colspan="1" rowspan="1">$150 - $170 million</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">$125 - $145&nbsp; million</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Effective Tax Rate on Adjusted Earnings(1)</td>
<td colspan="1" rowspan="1">16.5&nbsp;%</td>
<td colspan="1" rowspan="1">~ 18%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
</tbody>
</table>
</figure>

News

Guidance

Thomson Reuters Affirms FY24 Sales Guidance Of $7.27B Vs. $7.28B Estimate

Enpro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) reported quarterly earnings of $1.74 per share which missed the analyst consensus estimate of $1.87 by 6.95 percent. The company reported quarterly sales of $260.900 million which missed the analyst consensus estimate of $264.467 million by 1.35 percent. This is a 4.07 percent increase over sales of $250.700 million the same period last year.

Earnings

Earnings Misses

Enpro Q3 2024 Adj. EPS $1.74 Misses $1.87 Estimate, Sales $260.900M Miss $264.467M Estimate

WIIM

PLTR

Palantir shares are trading higher after the company reported better-than-expected Q3 financial results and issued guidance above consensus estimates.

MNDO

MIND C.T.I. Q3 EPS $0.04 Down From $0.06 YoY, Sales $5.21M Down From $5.26M YoY

Truist Securities analyst Jamie Cook upgrades MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) from Hold to Buy and raises the price target from $133 to $173.

Upgrades

Price Target

Analyst Ratings

Truist Securities Upgrades MasTec to Buy, Raises Price Target to $173

Enpro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) lowers FY2024 Adj EPS guidance from $7.00-7.60 to $6.75-7.00 vs $7.27 analyst estimate..

Enpro Lowers FY2024 Adj EPS Guidance from $7.00-7.60 to $6.75-7.00 vs $7.27 Est

Westlake Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLKP#NYSE">WLKP</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.36 by 41.67 percent. The company reported quarterly sales of $276.995 million which beat the analyst consensus estimate of $244.000 million by 13.52 percent. This is a 13.89 percent decrease over sales of $321.664 million the same period last year.

Earnings Beats

WLKP

Westlake Chemical Q3 2024 GAAP EPS $0.51 Beats $0.36 Estimate, Sales $276.995M Beat $244.000M Estimate

Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) affirms FY2024 sales outlook from $65.00 million-67.00 million to $65.00 million-67.00 million.

SOPH

Sophia Genetics Affirms FY2024 Sales Guidance to $65.00M-67.00M  VS Est. 65.66M

Biotech

Health Care

General

BEAM

Beam Therapeutics Ended Third Quarter 2024 With $925.8M In Cash, Cash Equivalents and Marketable Securities; Expected Operating Runway into 2027

Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) reported quarterly earnings of $1.48 per share which beat the analyst consensus estimate of $1.47 by 0.68 percent. This is a 14.73 percent increase over earnings of $1.29 per share from the same period last year. The company reported quarterly sales of $4.619 billion which beat the analyst consensus estimate of $4.566 billion by 1.16 percent. This is a 12.93 percent increase over sales of $4.090 billion the same period last year.

Emerson Electric Q4 2024 Adj. EPS $1.48 Beats $1.47 Estimate, Sales $4.619B Beat $4.566B Estimate

Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) reported quarterly earnings of $1.41 per share which missed the analyst consensus estimate of $2.21 by 36.2 percent. The company reported quarterly sales of $3.117 billion which missed the analyst consensus estimate of $3.305 billion by 5.69 percent. This is a 0.06 percent increase over sales of $3.115 billion the same period last year.

Westlake Q3 2024 Adj. EPS $1.41 Misses $2.21 Estimate, Sales $3.117B Miss $3.305B Estimate

Hyster Yale (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HY#NYSE">HY</a>) reported quarterly earnings of $0.97 per share which missed the analyst consensus estimate of $1.97 by 50.76 percent. This is a 52.91 percent decrease over earnings of $2.06 per share from the same period last year. The company reported quarterly sales of $1.02 billion which missed the analyst consensus estimate of $1.06 billion by 3.82 percent. This is a 1.50 percent increase over sales of $1.00 billion the same period last year.

Hyster Yale Q3 2024 GAAP EPS $0.97 Misses $1.97 Estimate, Sales $1.02B Miss $1.06B Estimate

Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.19) by 48.74 percent. This is a 45.08 percent decrease over losses of $(1.22) per share from the same period last year. The company reported quarterly sales of $14.27 million which missed the analyst consensus estimate of $14.50 million by 1.58 percent. This is a 17.01 percent decrease over sales of $17.19 million the same period last year.

Beam Therapeutics Q3 2024 GAAP EPS $(1.77) Misses $(1.19) Estimate, Sales $14.27M Miss $14.50M Estimate

Thomson Reuters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRI#NYSE">TRI</a>) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.77 by 3.9 percent. This is a 2.44 percent decrease over earnings of $0.82 per share from the same period last year. The company reported quarterly sales of $1.720 billion which beat the analyst consensus estimate of $1.713 billion by 0.39 percent. This is a 7.90 percent increase over sales of $1.594 billion the same period last year.

Thomson Reuters Q3 2024 Adj. EPS $0.80 Beats $0.77 Estimate, Sales $1.720B Beat $1.713B Estimate

Restaurant Brands International shares are trading lower following worse-than-expected Q3 financial results.

PINC

Premier Q1 2025 Adj. EPS $0.34 Beats $0.25 Estimate, Sales $248.142M Beat $232.843M Estimate

Restaurant Brands Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) reported quarterly earnings of $0.93 per share which missed the analyst consensus estimate of $0.95 by 2.11 percent. The company reported quarterly sales of $2.291 billion which missed the analyst consensus estimate of $2.307 billion by 0.69 percent. This is a 24.71 percent increase over sales of $1.837 billion the same period last year.

Restaurant Brands Intl Q3 2024 Adj. EPS $0.93 Misses $0.95 Estimate, Sales $2.291B Miss $2.307B Estimate

Edward Jones analyst David Heger downgrades BCE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCE#NYSE">BCE</a>) from Buy to Hold.

Downgrades

Edward Jones Downgrades BCE to Hold

B of A Securities analyst Dariusz Lozny upgrades MDU Resources Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDU#NYSE">MDU</a>) from Neutral to Buy and lowers the price target from $31 to $17.

B of A Securities Upgrades MDU Resources Gr to Buy, Lowers Price Target to $17

TD Cowen analyst Yaron Werber initiates coverage on Upstream Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>) with a Buy rating.

Initiation

TD Cowen Initiates Coverage On Upstream Bio with Buy Rating

An update from American Oncology Network (AONC) is now available. David H. Gould has announced his resignation as the principal financial officer a...

American Oncology Network Announces Key Officer Changes

American Oncology Network GAAP EPS of -$1.22, revenue of $364.34M

American Oncology Network, Inc. (AONC) Q1 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
American Oncology Network (NASDAQ:<a href="https://investorplace.com/stock-quotes/aonc-stock-quote/">AONC</a>) just reported results for the first quarter of 2024.<ul><li>American Oncology Network reported earnings per share of -$1.22.</li><li>The company reported revenue of $364.34 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/aonc-stock-earnings-american-oncology-network-for-q1-of-2024/">AONC Stock Earnings: American Oncology Network Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AONC Stock Earnings: American Oncology Network Reported Results for Q1 2024

American Oncology Network to delist its class A stock, warrants from Nasdaq

Tandem Diabetes Care, Guardion Health, GT Biopharma among healthcare movers

American Oncology Network appoints David Afshar as chief financial and operating officer

The latest update is out from American Oncology Network (AONC). The American Oncology Network, Inc. has appointed David Afshar as its new Chief Fin...

American Oncology Network Welcomes New CFO and COO

American Oncology Network GAAP EPS of -$0.11, revenue of $433.98M

Community oncology practice Florida Oncology and Hematology, a partner practice of American Oncology Network (AONC), is announces patients now have...

American Oncology Network partner opens new location in Cape Coral

AONC

AONCW

BDRX

GHSI

GTBP

LSDI

MYMD

SABS

TNDM

XYLO

Press Releases

American Oncology Network Announces Voluntary Delisting From Nasdaq

Management

American Oncology Network Appoints David Afshar as Chief Financial and Operating Officer

American Oncology Network Announces the Research Studies Presented at the ASCO 2024 Annual Meeting

American Oncology Network Expands Radiation Oncology Services, Opens New Clinic

OTC Markets Group Welcomes American Oncology Network, Inc. to OTCQX

American Oncology Network Announces the Commencement of OTCQX Trading

Indianapolis Medical Oncologist Co-authors Research Presented at International Lymphoma Symposium

American Oncology Network Announces Second Quarter 2024 Earnings Release Date and Conference Call

Florida Oncology and Hematology and American Oncology Network Opens New Location in Cape Coral, Welcomes Medical Director, Dr. Van den Bergh, and Drs. Venkata Parsa, and Shivtaj Mann

Comments

American Oncology Network

American Oncology Network (AONC) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO